Skip to content
Medicines & Healthcare products Regulatory Agency
The National Institute for Biological Standards and Control

Confidence in biological medicines

  • Stay connected
  • Shopping Basket
  • Pay Now
  • Login / Register
  • Home
  • Products
  • Standardisation
  • Control testing
  • Science and research
  • Expert services
  • About us
  • Latest news
  • Worldwide impact of NIBSC
  • Mission and values
  • Careers
  • Quality and governance
  • Staff profiles
  • Contact us
  • Collaborations
  • Suppliers
  • Scientific Advisory Committee
  • Minutes of the Animal Welfare and Ethical Review Body
  • Our use of animals
  • Privacy notice
  • Home  /  
  • About us  /  
  • Staff profiles  /  
  • Dr Mei Mei Ho

Dr Mei Mei Ho

Dr Mei Mei Ho is a principal scientist at NIBSC. Her team in the Bacteriology Division focuses on research and development (R&D), quality control and the standardisation of biological medicines used in tuberculosis and malaria.

Her laboratory is accredited to ISO/IEC 17025 and is responsible for batch release and standardisation of mycobacterial products, such as Lyophilised BCG.

Dr Ho has worked at NIBSC since 1998 and leads R&D and standardisation projects, includes collaborating with vaccine manufacturers in the laboratory evaluation of product characterisation and quality control assays for novel bacterial vaccines, such as:

  • protein subunit
  • polysaccharide-protein conjugates
  • viral vector
  • live bacterial vaccines

Before joining NIBSC, she received her scientific training at Queen Mary College, University of London where she completed her PhD studies in the fields of endocrinology and biochemistry. She then focused her research in protein biochemistry and molecular biology in her fellowship years at University College London.

 
Current position

Principal Scientist and Group Leader, Division of Bacteriology

Areas of interest

Tuberculosis
Malaria
Vaccine product development

Qualifications

1994: PhD in endocrinology and biochemistry, Queen Mary College, University of London

Publications (PDF, 64KB)

Representation on external committees

Product Development Team in Tuberculosis Vaccine Initiative
BCG working group in World Health Organisation

Representation on EU consortia

Nanotheraputics for Antibiotic Resistent Emerging Bacterial pathogens (NAREB)
European Research Infrastructures for Poverty Related Diseases (EURIPED)
Biomarkers for enhanced vaccines immunosafety (BioVacSafe)
European network of vaccine research and development TRANSVAC
Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development (TBVAC2020)

  • Careers
  • Terms and conditions
  • Accessibility
  • Privacy notice
  • Cookies
  • Sitemap